Stanford Cancer Institute
Stanford, California, United States
Dr. Jason Gotlib is Professor of Medicine in the Division of Hematology at the Stanford Stanford Cancer Institute where he is leader of the hematology clinical research group. Dr. Gotlib's research focus is clinical and translational evaluation of novel therapies for myeloproliferative neoplasms, including JAK inhibitors and other novel drugs for myelofibrosis, KIT inhibitors for systemic mastocytosis, and targeted agents for eosinophilia. He has authored more than 250 research articles, chapters, and reviews that have been published in journals such as Blood, Journal of Clinical Oncology, Nature Medicine, and The New England Journal of Medicine. Dr. Gotlib is Vice-Chair of the NCCN Guidelines Committee on Myeloproliferative Neoplasms, and led development of NCCN Guidelines for systemic mastocytosis. He is also a co-founding Steering Committee Member of the American Initiative in Mast Cell Diseases (AIM), the first pan-American organization dedicated to the research of mast cell disorders. Dr. Gotlib is actively involved with the American Society of Hematology where he has served as Editor-in-Chief of ASH’s The Hematologist, Educational Co-Chair for the 2019 ASH Annual Meeting, and is a Podcast Editor for the journal Blood.
Disclosure information not submitted.
Wednesday, October 19, 2022
4:25 PM – 6:00 PM
Wednesday, October 19, 2022
5:10 PM – 5:30 PM
Wednesday, October 19, 2022
5:30 PM – 6:00 PM